Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Titel:
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial
Auteur:
Platzbecker, Uwe Santini, Valeria Fenaux, Pierre Sekeres, Mikkael A Savona, Michael R Madanat, Yazan F Díez-Campelo, Maria Valcárcel, David Illmer, Thomas Jonášová, Anna Bělohlávková, Petra Sherman, Laurie J Berry, Tymara Dougherty, Souria Shah, Sheetal Xia, Qi Sun, Libo Wan, Ying Huang, Fei Ikin, Annat Navada, Shyamala Feller, Faye Komrokji, Rami S Zeidan, Amer M